Botanical and Plant-Derived Drugs Market Size to grow by USD 20.93 billion between 2024-2028
According to a research report “ Botanical and Plant-Derived Drugs Market” by Type (Oral, Injectables, Topicals) Application (Infectious diseases, Central nervous system, Cardiovascular diseases, Respiratory diseases, Digestive diseases and others) Geography (Asia, Europe, North America, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 20.93 billion, at a CAGR of 8.18% during the forecast period. In the healthcare sector, there is a growing recognition of the potential of botanical and plant-derived drugs in providing safe and effective treatments. Governments worldwide are taking proactive measures to foster research, development, and commercialization in this area. For instance, the European Medicines Agency (EMA) approved Vaxarol, a plant-based drug derived from seaweed, for the treatment of respiratory conditions in 2022. This regulatory milestone not only validated the potential of plant-based medicines but also stimulated increased investment in research and development within the market. Furthermore, the World Health Organization (WHO) and the Government of India signed an agreement in March 2022 to establish the Global Centre for Traditional Medicine (GCTM) in Gujarat, India, underscoring the commitment to advancing traditional medicine through modern scientific methods.
Browse market data tables, figures, and in-depth TOC on “Botanical and Plant-Derived Drugs Market” by Type (Oral, Injectables, Topicals) Application (Infectious diseases, Central nervous system, Cardiovascular diseases, Respiratory diseases, Digestive diseases and others) Geography (Asia, Europe, North America, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Type, the Oral segment is projected to dominate the market size in 2024
The global botanical and plant-derived drugs market is experiencing significant growth, particularly in the infectious diseases segment. This trend is driven by the rising prevalence of infectious diseases such as hepatitis, influenza, and HIV. These diseases, which are caused by harmful microorganisms like bacteria, viruses, parasites, and fungi, pose a substantial threat to global health. They can result in high mortality rates, debilitating disabilities, or unpredictable and far-reaching impacts on populations. The increasing burden of these diseases is expected to fuel the demand for botanical and plant-derived drugs during the forecast period.
By Application, Infectious diseases segment is expected to hold the largest market size for the year 2024
The oral segment of the global botanical and plant-derived drugs market encompasses various forms, including tablets, capsules, oral solutions, and liquid concentrates. Among these, oral solutions represent a versatile and convenient drug type, favored by both consumers and healthcare providers. These solutions offer ease of administration and rapid absorption, making them a popular choice in the botanical and plant-based drugs market. Tinctures, a specific type of oral solution, have gained significant traction due to their concentrated plant-derivative compositions, enabling precise dosage control and straightforward administration. Pierre Fabre SA is a notable player in this market, offering botanical and plant-derived drugs in the form of tinctures, such as Permixon, which is utilized for the treatment of urinary symptoms associated with Benign Prostatic Hyperplasia (BPH).
Asia is forecasted to hold the largest market size by region in 2024
The Asia region is projected to exhibit the most significant growth in the botanical and plant-derived drugs market during the forecast period. This can be attributed to the abundant availability of a diverse range of plant species in the region. For instance, India, as per the National Institutes of Health (NIH), hosts approximately 45,000 plant species, many of which are claimed to exhibit medicinal properties. Extensive research has revealed that several plants possess antihistaminic, antiasthmatic, and antiallergic activities. Moreover, the China Food and Drug Administration (CFDA) has authorized the commercialization of around eight fungal glycan-based drugs, which have demonstrated efficacy against various diseases. The use of plant-derived remedies for disease treatment is deeply rooted in China's cultural heritage.
The Botanical and Plant-Derived Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Botanical and Plant-Derived Drugs market encompasses a wide range of natural substances derived from vegetable material, medicinal plants, fungi, algae, bacteria, and Archaea. These natural products play a significant role in the treatment of various diseases, including infectious diseases, respiratory diseases, cardiovascular diseases, and lifestyle diseases. Terpenes and steroids are among the key active compounds found in these sources, which have shown therapeutic potential against bacteria, fungi, and viruses. FDA-approved plant-derived drugs, such as Artemisinin from Artemisia annua for malaria and Paclitaxel from Taxus brevifolia for cancer, are just a few examples of the performance and efficiency that natural substances can offer in the healthcare industry. Herbal medicines and botanical drugs have gained increasing attention due to their potential to provide effective treatments with minimal side effects. The global botanical drugs market is expected to grow significantly due to the ongoing research and development in this field, as well as the increasing demand for natural and sustainable therapeutic medicines.
Market Research Overview
The Botanical and Plant-Derived Drugs Market encompasses a wide range of therapeutic agents derived from medicinal plants, fungi, algae, and other vegetable materials. Companies like Aimil Pharmaceuticals are at the forefront of this industry, developing botanical drugs for various indications. For instance, Mytesi, their antidiarrheal drug, is used to treat acute respiratory syndrome in HIV-infected patients. As the world shifts towards more natural therapeutic approaches, the demand for plant-derived drugs is on the rise. These drugs offer alternatives to conventional synthetic drugs, which can come with side effects and risks, such as allergic reactions, drugs recalls, and gastrointestinal upsets. Botanical drugs have shown potential in treating chronic diseases like chronic pain, intractable chronic pain, and cancer. They include FDA-approved drugs like Vinca Alkaloids, Ergot Alkaloids, Morphine Alkaloids, Glycosides, Terpenes and Steroids, and microbial fermentation products. Moreover, the market extends to non-medicinal plant substances used in toiletries, cosmetics, pharmaceutical excipients, and intravenously delivered nutrients like NutraProtein Power Blend (Hemp Protein Powder and Pea Protein Powder), Nopal Powder, and Yacon Leaf Powder. The botanical drugs market is a growing sector, driven by public awareness, medicinal approaches, and the cancer therapeutic potential of natural substances. It caters to various diseases, including infectious diseases, respiratory diseases, cardiovascular diseases, breast disease, and lifestyle diseases like diabetes and chronic diseases. The younger age group is increasingly turning to botanical drugs for their performance and efficiency, as they seek natural alternatives to synthetic drugs. The market's growth is further fueled by advancements in biotechnology, including the exploration of marine life and the use of technical experts to develop new plant-derived drugs. In conclusion, the Botanical and Plant-Derived Drugs Market is a dynamic and expanding sector, offering innovative solutions to meet the evolving healthcare needs of humans. It encompasses a diverse range of products, from herbal medicines to specialty drugs, and caters to various indications, from infectious diseases to chronic diseases. With continued investment and research, the potential for botanical drugs to improve life expectancy and enhance overall health is immense.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
